Table 1 Clinical characteristics, treatments and outcomes of patients with hematological malignancies and SARS-CoV-2 infection.
From: COVID-19 outcomes in patients with hematologic disease
Patient No | Age | Sex | BMI | Hemalogical disease | Hematological status | Hematological treatment | Ongoing corticosteroids | Number of treatment lines | Previous transplant | Comorbidities | Time between onset of symptoms and diagnosis (days) | Radiologic diagnosis | ARDS | Invasive mechanical ventilation | COVID-19 management | Follow-up since first symptoms (days) | Survival status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 65 | M | 28.7 | Myeloma | Complete remission | Ongoing isatuximab + DXM maintenance | Yes | 2 | Autologous | HBP | 3 | Positive CT | Yes | Yes | Best supportive care | 17 | Dead |
2 | 73 | F | 30.2 | Myeloma | Diagnosis | None | No | 0 | No | Diabetes, HBP, stroke, obesity | 4 | Positive X-ray | Yes | Yes | Best supportive care | 13 | Dead |
3 | 65 | M | 24.3 | Myeloma | Complete remission | Ongoing lenalidomide maintenance | No | 1 | Autologous | HBP | 4 | ND | No | No | HCQ/AZT + Tociluzumab | 40 | Alive |
4 | 61 | M | 41.5 | Lymphoma (DLBCL) | Complete remission | None, 3 months post CAR T-cell | No | 4 | Autologous and allogeneic | Diabetes, HBP, obesity | 7 | Positive CT | Yes | Yes | Best supportive care | 38 | Alive |
5 | 61 | F | 31.6 | Myeloma | Partial remission | Ongoing carfilzomib + lenalidomide + DXM | Yes | 6 | Autologous | Diabetes, HBP, stroke, obesity | 7 | Positive CT | No | No | Lopinavir-ritonavir | 34 | Alive |
6 | 45 | M | 45.8 | PNH | Partial remission | Ongoing eculizumab | No | 1 | No | Obesity | 4 | Positive CT | Yes | Yes | Best supportive care | 32 | Alive |
7 | 40 | F | 26.7 | ALL | Complete remission | None, 9 months post allo-HSCT | No | 1 | Allogeneic | No | 0 | Positive CT | Yes | Yes | Best supportive care | 23 | Alive |
8 | 78 | M | 26.3 | MDS | Progressive disease | Best supportive care | Yes | 0 | No | Glioma, stroke | 1 | Positive X-ray | Yes | No | Tociluzumab + corticosteroids | 10 | Dead |
9 | 79 | M | 37.8 | Lymphoma (hairy cell) | Complete remission | None, 12 years post Cladribine | No | 2 | No | HBP, obesity, CKD, MDS, MGUS | 2 | Positive X-ray | No | No | Lopinavir-ritonavir | 26 | Alive |
10 | 62 | F | 24.2 | LGL leukemia | Complete remission | None, 18 months post cyclophosphamide | No | 1 | No | No | 1 | Positive CT | No | No | Best supportive care | 32 | Alive |
11 | 75 | M | 28.7 | MDS | Progressive disease | Best supportive care | No | 0 | No | Diabetes, HBP | 7 | Positive CT | Yes | No | Best supportive care | 27 | Dead |
12 | 81 | M | 21.3 | Myeloma | Partial remission | Ongoing lenalidomide + DXM | Yes | 1 | No | HBP | 3 | Positive CT | Yes | No | Best supportive care | 10 | Dead |
13 | 81 | M | 30.1 | Lymphoma (Marginal zone) | Progressive disease | None, 14 months post rituximab + bendamustine | No | 1 | No | Diabetes, HBP, stroke, obesity, COPD | 0 | ND | No | No | Best supportive care | 35 | Alive |
14 | 63 | M | 25.0 | Lymphoma (hairy cell) | Complete remission | None, 5 years post rituximab | No | 2 | No | HBP | 5 | ND | No | No | Best supportive care | 32 | Alive |
15 | 92 | M | 20.0 | Myeloma | Progressive disease | Ongoing cyclophosphamide + prednisone | Yes | 3 | No | HBP | 14 | Positive X-ray | Yes | No | Best supportive care | 14 | Dead |
16 | 89 | M | 23.6 | Myeloma | Stable disease | Ongoing lenalidomide + DXM | Yes | 2 | No | CKD | 6 | Positive CT | Yes | No | Best supportive care | 21 | Dead |
17 | 61 | M | 23.9 | Myeloma | Complete remission | Ongoing bortezomib maintenance | No | 2 | Autologous | Cardiomyopathy | 12 | Positive X-ray | No | No | Best supportive care | 29 | Alive |
18 | 86 | M | 22.3 | CLL | Stable disease | Wait and watch | No | 0 | No | HBP, stroke, CKD | 10 | Positive X-ray | Yes | No | Lopinavir-ritonavir + corticosteroids | 17 | Dead |
19 | 68 | F | 24.4 | Myeloma | Partial remission | Ongoing daratumumab + lenalidomide + DXM | Yes | 2 | No | Diabetes, HBP | 1 | Positive CT | Yes | Yes | Lopinavir-ritonavir + corticosteroids + tociluzumab | 17 | Alive |
20 | 72 | F | 31.5 | Myeloma | Partial remission | Ongoing daratumumab + lenalidomide + DXM | Yes | 1 | No | HBP, obesity | 0 | Positive CT | No | No | Best supportive care | 20 | Alive |
21 | 76 | M | 19.3 | MDS | Progressive disease | Best supportive care | No | 1 | No | CKD, COPD | 3 | Positive CT | No | No | Best supportive care | 20 | Alive |
22 | 97 | F | 17.2 | MDS | Progressive disease | Best supportive care | No | 1 | No | Pancreatic adenocarcinoma, CKD | 2 | ND | Yes | No | Best supportive care | 4 | Dead |
23 | 71 | M | 24.1 | Lymphoma (DLBCL) | Complete remission | Ongoing rituximab maintenance | No | 2 | Autologous | HBP, stroke | 22 | Positive CT | No | No | Anakinra | 29 | Alive |
24 | 63 | M | 22.8 | Lymphoma (Poppema) | Complete remission | Ongoing rituximab-CHOP | Yes | 1 | No | HBP | 10 | Positive X-ray | No | No | Best supportive care | 19 | Alive |
25 | 75 | F | 41.4 | Waldenström macroglobulinemia | Partial remission | Ongoing rituximab + cyclophosphamide + DXM | Yes | 3 | No | HBP, obesity, epidermoid carcinoma of the anal canal | 1 | Positive CT | No | No | Best supportive care | 14 | Alive |
